NCT06585722

Brief Summary

Fluid resuscitation is one of the cornerstones of treatment in ICU patients. Nonetheless, excessive fluid administration can lead to fluid overload which has been associated with worse outcomes in the ICU. To prevent this, assessments of fluid responsiveness are commonly employed. However, fluid responsiveness does not take fluid tolerance into account. Fluid tolerance is the idea that a patient might still be fluid responsive but might already be at risk of the detrimental effects of fluid therapy. Recent developments in point of care ultrasound e.g. the Venous excess ultrasound might help identify patients at risk of fluid overload. However its association with patient relevant outcomes in the ICU remains unclear.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
136

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2023

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

March 13, 2024

Completed
6 months until next milestone

First Posted

Study publicly available on registry

September 5, 2024

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 5, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 5, 2024

Completed
Last Updated

September 5, 2024

Status Verified

September 1, 2024

Enrollment Period

1.6 years

First QC Date

March 13, 2024

Last Update Submit

September 4, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Rate of acute kidney injury

    Clinically relevant acute kidney injury in the ICU: a 200% rise in creatinine or the use of renal replacement therapy

    within 30 days of admission to the ICU

  • Mortality

    death of all causes

    within 30 days of admission to the ICU

  • Rate of MAKE-30

    a composite endpoint of mortality and acute kidney injury ( including renal replacement therapy)

    within 30 days of admission to the ICU

Other Outcomes (2)

  • Lung ultrasound score

    maximum of 3 times during the first 7 days of admission

  • Cardiac function as assed by ultrasound

    maximum of 3 times during the first 7 days of admission

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All cricitally ill patients who are expected to be admitted to the ICU for more than 24 hours and who do not meet the exclusion criteria

You may qualify if:

  • all patients admitted to the ICU 18 years or older expected to stay in the ICU for more than 24 hours

You may not qualify if:

  • any obstruction between the righ atrium and structures assessed by VExUS
  • a medical history of: Major cardiac shunts (e.g. atrial septum defect), Tricuspid regurgitation, dialysis, portal hypertension, pulmonary hypertension, interstitial lung disease, recipients of a kidney of liver transplant.
  • patients in whom an ultrasound assesment is unfeasible e.g. a BMI over 40

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Amsterdam UMC

Amsterdam, North Holland, 1081HV, Netherlands

RECRUITING

MeSH Terms

Conditions

Edema

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Pieter R Tuinman, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. P.R. Tuinman, Principal Investigator

Study Record Dates

First Submitted

March 13, 2024

First Posted

September 5, 2024

Study Start

February 1, 2023

Primary Completion

September 5, 2024

Study Completion

September 5, 2024

Last Updated

September 5, 2024

Record last verified: 2024-09

Locations